HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS

STARTRK-NG (phase 1/2) is evaluating entrectinib, a CNS-penetrant oral, TRK/ROS1/ALK tyrosine kinase inhibitor, in patients <21 years with recurrent/refractory solid tumors, including primary CNS tumors. After determining the recommended dose, 550mg/m(2)/day, in all-comers, expansion cohorts with...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Giles, Desai, Ami, Basu, Ellen, Foster, Jennifer, Gauvain, Karen, Sabnis, Amit, Shusterman, Suzanne, Macy, Margaret, Mease, Luke, Yoon, Janet, Cash, Thomas, Abdelbaki, Mohamed, Nazemi, Kellie, Pratilas, Christine, Weiss, Brian, Chohan, Saibah, Cardenas, Alison, Hutchinson, Katherine, Bergthold, Guillaume, Gajjar, Amar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
High Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715329/
http://dx.doi.org/10.1093/neuonc/noaa222.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715329/
http://dx.doi.org/10.1093/neuonc/noaa222.293

Ejemplares similares